Solid Tumors Clinical Trial
Official title:
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
Verified date | March 2016 |
Source | Tesaro, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer,
including:
1. Anaplastic lymphoma kinase (ALK)
2. The tropomyosin-related kinases TRKA, TRKB, and TRKC
This is a sequential, open-label, non-randomized study with dose escalation in Phase 1,
followed by expansion at a recommended phase 2 dose.
Status | Completed |
Enrollment | 72 |
Est. completion date | June 2018 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - To be considered eligible to participate in this study, all of the following requirements must be met: 1. Patients in Phase 1 must have metastatic or locally advanced solid tumors who have failed to respond to standard therapy 2. All patients must have confirmation of either ALK positive or TRK positive status. 3. Patients in Phase 1 will not be required to have measurable disease. All patients in Phase 2a will be required to have measurable disease by RECIST. 4. All patients enrolled in this study must have tumor tissue available. 5. Patient (male or female) must be = 18 years of age (except where age of majority is 16 years in a particular country, such as the United Kingdom). 6. Patient must have performance status =2 on the ECOG Performance Scale. 7. Patient must have an estimated life expectancy of at least 3 months. 8. Patients must have adequate organ function. 9. For patients previously treated with myelosuppressive therapy, at least 3 weeks must have elapsed and toxicity must have recovered to grade 1 or baseline. Non-myelosuppressive therapy patients must have recovered from all treatment-related toxicities. Fourteen days must have elapsed since palliative radiation for bone metastasis. 10. Female patients of childbearing potential must have a negative serum pregnancy test and use adequate birth control for the duration of study participation and for 3 months after the last dose of study drug. 11. The patient or his or her legal representative must be able to read, understand, and provide signed informed consent. 12. Patient is able to understand the study procedures and agrees to participate in the study by giving written informed consent. Exclusion Criteria: - Patients will not be deemed eligible for entry into this study if any of the following criteria are met: 1. Patient has leukemia. 2. Patient is a pregnant or lactating female. 3. Patient has uncontrolled congestive heart failure, angina, or has had a myocardial infarction in the preceding 3 months. 4. Ongoing cardiac dysrhythmias of NCI CTCAE Grade =2, atrial fibrillation of any grade, or QTc interval >450 msec. 5. Patients with risk factors for Torsade de point and patients receiving concomitant medication with QT-prolonging medicines. 6. Patient has an uncontrolled concurrent medical condition or disease. 7. Patient has undergone bone marrow or stem cell transplantation in the past 6 months. 8. Patient has a known hypersensitivity to the components of TSR-011 or the excipients. 9. Patient has active or uncontrolled infection. 10. Patient has a known psychiatric or substance abuse disorder. 11. Patient has active second primary malignancy. 12. Patient is observed to have a clinically active central nervous system (CNS) metastases or carcinomatous meningitis. 13. Patient has any other severe concurrent disease which, in the judgment of the Investigator, would preclude study participation. 14. Patient is known to be HIV positive or who has an AIDS-related illness. 15. Patient has a known history of or active (treated or not) Hepatitis B or C. 16. Patient has presence of ascites causing significant symptoms. 17. A patient must stop taking any prescription, over-the-counter, or herbal remedy known to be an inhibitor or inducer of CYP3A4/5. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Tesaro, Inc. |
United States, Poland, Spain, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events (AEs) | Approximately 2 years | ||
Secondary | Area Under the Concentration-Time Curve (AUC) | Day 1: 0-24 hrs after first dose; pre-dose on days 8 & 15; day 29: 0-24 hours | ||
Secondary | Maximum Tolerated Dose (MTD) | Phase 1, during the dose-escalation phase | 28 days after first dose | |
Secondary | Response Rate (RR) | Phase 2 | approximately 2 years | |
Secondary | Dose limiting toxicity (DLT) | Phase 1, during the dose escalation phase | 28 days after first dose | |
Secondary | Progression Free Survival (PFS) | Phase 2 | approximately 2 years | |
Secondary | Recommended Phase 2 Dose (RP2D) | Phase 1 | approximately 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |